Mitral Valve Restenosis After Percutaneous Transmitral Valvuloplasty, Role of Continuous Inflammation

Overview

Journal J Cardiovasc Thorac Res

Specialty Cardiology & Vascular Diseases

Date 2014 Oct 17

PMID 25320668

Citations 2

Authors

Mohammadali Ostovan

Amir Aslani

Shahima Abounajmi

Vida Razazi

Affiliations

Soon will be listed here.

Abstract

Introduction: High sensitive C-Reactive Protein (hs-CRP) is increased in acute and chronic rheumatic fever (RF), but is unknown whether serum levels of hs-CRP is correlated with late restenosis of mitral valve (MV) after Percutaneous transvenous mitral commissurotomy (PTMC). The aim of this study is to determine relationship between hs-CRP and MV restenosis 48-36 months after performing PTMC.

Methods: A total of 50 patients who had undergone PTMC due to rheumatic etiology (41 female, 9 male; mean age 46 ± 11, range 27-71), all followed up on an out patients basis 36 months after PTMC, were included in the study. The hs-CRP was measured using an enzyme-linked immunosorbent assay (ELISA) kits.

Results: No association was found between hs-CRP level and mean transmitral valve gradient 36 months after PTMC, MV area by planimetry, pulmonary artery systolic pressure, mitral regurgitation grade, left atrial diameter, atrial fibrillation (AF) rhythm and Wilkins score.

Conclusion: Our study have shown that there is no association between hs-CRP and MV restenosis in patients with rheumatic heart disease (RHD) who underwent PTMC. Therefore, it has been postulated that inflammation is not a cause of post PTMC restenosis.

Citing Articles

Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease.

Noubiap J, Nyaga U, Ndoadoumgue A, Nkeck J, Ngouo A, Bigna J Glob Heart. 2020; 15(1):38.

PMID: 32923332 PMC: 7427678. DOI: 10.5334/gh.807.

Predicting outcome after percutaneous balloon mitral commissurotomy : Role of neutrophil-lymphocyte ratio.

Separham A, Pourafkari L, Bodagh H, Ghaffari S, Aslanabadi N, Nader N Herz. 2016; 42(5):509-514.

PMID: 27796408 DOI: 10.1007/s00059-016-4488-3.

References

Shine B, de Beer F, Pepys M . Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta. 1981; 117(1):13-23. DOI: 10.1016/0009-8981(81)90005-x. View

Chiu-Braga Y, Hayashi S, Schafranski M, Messias-Reason I . Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol. 2005; 109(2):275-6. DOI: 10.1016/j.ijcard.2005.04.030. View

Selcuk M, Selcuk H, Maden O, Temizhan A, Aksu T, Dogan M . Relationship between inflammation and atrial fibrillation in patients with isolated rheumatic mitral stenosis. J Heart Valve Dis. 2007; 16(5):468-74. View

Block P, Palacios I, BLOCK E, Tuzcu E, Griffin B . Late (two-year) follow-up after percutaneous balloon mitral valvotomy. Am J Cardiol. 1992; 69(5):537-41. DOI: 10.1016/0002-9149(92)91000-t. View

Hasan-Ali H, Shams-Eddin H, Abd-Elsayed A, Maghraby M . Echocardiographic assessment of mitral valve morphology after Percutaneous Transvenous Mitral Commissurotomy (PTMC). Cardiovasc Ultrasound. 2007; 5:48. PMC: 2248162. DOI: 10.1186/1476-7120-5-48. View

Abascal V, Wilkins G, Choong C, Thomas J, Palacios I, Block P . Echocardiographic evaluation of mitral valve structure and function in patients followed for at least 6 months after percutaneous balloon mitral valvuloplasty. J Am Coll Cardiol. 1988; 12(3):606-15. DOI: 10.1016/s0735-1097(88)80045-7. View

Saeki F, Ishizaka Y, Tamura T . Long-term clinical and echocardiographic outcome in patients with mitral stenosis treated with percutaneous transvenous mitral commissurotomy. Jpn Circ J. 1999; 63(8):597-604. DOI: 10.1253/jcj.63.597. View

Gerber I, Stewart R, Hammett C, Legget M, Oxenham H, West T . Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol. 2003; 92(9):1129-32. DOI: 10.1016/j.amjcard.2003.07.012. View

Golbasi Z, Ucar O, Keles T, Sahin A, Cagli K, Camsari A . Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail. 2002; 4(5):593-5. DOI: 10.1016/s1388-9842(02)00102-2. View

10.

Berger M . Natural history of mitral stenosis and echocardiographic criteria and pitfalls in selecting patients for balloon valvuloplasty. Adv Cardiol. 2004; 41:87-94. DOI: 10.1159/000079787. View

11.

Yeun J, Levine R, Mantadilok V, Kaysen G . C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35(3):469-76. DOI: 10.1016/s0272-6386(00)70200-9. View

12.

Nobuyoshi M, Hamasaki N, Kimura T, Nosaka H, Yokoi H, Yasumoto H . Indications, complications, and short-term clinical outcome of percutaneous transvenous mitral commissurotomy. Circulation. 1989; 80(4):782-92. DOI: 10.1161/01.cir.80.4.782. View

13.

Yonga G, Bonhoeffer P . Percutaneous transvenous mitral commissurotomy in juvenile mitral stenosis. East Afr Med J. 2003; 80(4):172-4. DOI: 10.4314/eamj.v80i4.8637. View

14.

Guilherme L, Cunha-Neto E, Coelho V, SNITCOWSKY R, Pomerantzeff P, Assis R . Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation. 1995; 92(3):415-20. DOI: 10.1161/01.cir.92.3.415. View

15.

Kushner I . C-reactive protein in rheumatology. Arthritis Rheum. 1991; 34(8):1065-8. DOI: 10.1002/art.1780340819. View

16.

Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C . Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998; 97(5):425-8. DOI: 10.1161/01.cir.97.5.425. View

17.

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

18.

Essop M, Nkomo V . Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005; 112(23):3584-91. DOI: 10.1161/CIRCULATIONAHA.105.539775. View

19.

Palacios I, Block P, Wilkins G, Weyman A . Follow-up of patients undergoing percutaneous mitral balloon valvotomy. Analysis of factors determining restenosis. Circulation. 1989; 79(3):573-9. DOI: 10.1161/01.cir.79.3.573. View

20.

Alyan O, Metin F, Kacmaz F, Ozdemir O, Maden O, Topaloglu S . High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis. J Thromb Thrombolysis. 2008; 28(1):63-9. DOI: 10.1007/s11239-008-0245-7. View